Document Detail


Clobazam therapy of refractory epilepsy in tuberous sclerosis complex.
MedLine Citation:
PMID:  23219029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clobazam (CLB) was recently approved by the FDA, but has not been evaluated in tuberous sclerosis complex (TSC). We retrospectively reviewed a cohort of patients with TSC and refractory epilepsy who started CLB over a 5-year period. Clinical characteristics and number of tubers on MRI were assessed. Duration of therapy, therapeutic response and adverse events were recorded. CLB was prescribed in 29 adults and children of whom 72% were cognitively impaired, with a median age at seizure onset of 5 months. Mean duration of CLB therapy was 17.3 months with a 12 and 24-month estimated retention rate of 82% and 68%, respectively. Twenty patients (69%) reported a good response (>50% seizure reduction) at the end of the titration, and six patients (21%) remained good responders after 12 months of CLB therapy. Adverse events occurred in 13 patients, predominantly somnolence and behavioral disorders. One quarter of the responders reported improvement in behavior. No predictive factor for a good response could be identified. CLB appears to be a well-tolerated and valuable option for treatment of refractory epilepsy in TSC.
Authors:
Melanie Jennesson; Agnies M van Eeghen; Paul A Caruso; Jan L Paolini; Elizabeth A Thiele
Related Documents :
19608549 - State-of-the-art review: assessing the safety profiles of new anticoagulants for major ...
16151059 - Experience with the recovery filter as a retrievable inferior vena cava filter.
10775029 - Simple and safe method to prepare patients with prosthetic heart valves for surgical de...
7726699 - Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events...
19683639 - Percutaneous closure of the left atrial appendage versus warfarin therapy for preventio...
639199 - Anticoagulant therapy and central nervous system complications in patients with prosthe...
21871279 - Late aortic insufficiency related to poor prognosis during left ventricular assist devi...
15708179 - Impact of medical treatment on lung diffusion capacity in elderly patients with heart f...
22066559 - Similar tka designs with differences in clinical outcome: a randomized, controlled tria...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-12-03
Journal Detail:
Title:  Epilepsy research     Volume:  104     ISSN:  1872-6844     ISO Abbreviation:  Epilepsy Res.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-30     Completed Date:  2013-11-14     Revised Date:  2013-12-05    
Medline Journal Info:
Nlm Unique ID:  8703089     Medline TA:  Epilepsy Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  269-74     Citation Subset:  IM    
Copyright Information:
Copyright © 2012. Published by Elsevier B.V.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anticonvulsants / therapeutic use*
Benzodiazepines / therapeutic use*
Child
Child, Preschool
Epilepsy / complications,  drug therapy*
Humans
Male
Retrospective Studies
Treatment Outcome
Tuberous Sclerosis / complications*,  drug therapy
Young Adult
Chemical
Reg. No./Substance:
0/Anticonvulsants; 12794-10-4/Benzodiazepines; 2MRO291B4U/clobazam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduced densities of parvalbumin- and somatostatin-expressing interneurons in experimental cortical ...
Next Document:  Involvement of ?4?2 nicotinic acetylcholine receptors in working memory impairment induced by repeat...